At the current share price of $28, the stock is trading at a reasonable 29 times 2025 earnings estimates. Analysts currently expect Celsius to return to revenue growth in 2025 before accelerating to a double-digit increase in 2026. Assuming those estimates hold up, the stock offers enough value right now to support more gains.

Nevertheless, growth stocks outperformed value stocks in 2024, and investors anticipate that trend will continue as the Federal Reserve cuts interest rates. Here are 10 of CFRA analysts' top growth stocks that have reported at least 15% annual revenue growth in the past three years:

Biote: Revolutionizing Hormone Optimization Biote (NYSE: BTMD) represents an innovative play in the growing hormone optimization market.

Here's your quick 5-minute guide on how to identify Canadian growth stocks. The post What to Know About Canadian Growth Stocks for 2025 appeared first on The Motley Fool Canada.

To the disappointment of buy-and-hold investors, 2025 is shaping up to be a year where nimble traders are likely to see the biggest gains. That said, there’s nothing wrong with the steady performance offered by blue-chip stocks—a sound strategy for many investors.